Investigating the Neural Circuits of Itch
研究瘙痒的神经回路
基本信息
- 批准号:8417905
- 负责人:
- 金额:$ 32.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-02-11 至 2018-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAgonistAnatomyBehaviorBehavioralBehavioral AssayBiological AssayBrainCellsChronicClinicalComplexCutaneousDermatologistDevelopmentDynorphinsEsthesiaFutureGenerationsGoalsHealthHeatingHumanHypersensitivityInterneuronsLabelLeadLogicMediatingMolecularMolecular GeneticsMusNervous system structureNeuronsNociceptionPainPlayProcessPruritusQuality of lifeRegulationResearchRodentRoleSensorySiteSkinSpecificitySpinalSpinal CordSpinal cord posterior hornTestingVisceralVisitWitbasecellular targetingclinically relevantdorsal horneffective therapyinsightkappa opioid receptorsmanneural circuitpainful neuropathypublic health relevancerelating to nervous systemresearch studysensory stimulusskin lesiontranscription factor
项目摘要
DESCRIPTION (provided by applicant): Chronic itch (puritis) is a severe condition that results in severely diminished quality of life. Moreover, this condition is much more widespread than generally appreciated, representing the most common reason to visit a dermatologist, despite the fact that treatments are generally ineffective. However, while itch is initiated in the skin, i is more than just a skin condition. Rather, itch is a complex and poorly understood sensation that is mediated by neural circuits in the periphery, the spinal cord and the brain. Thus, the long-term
goal of our research is to gain a better understanding of the neural circuits that mediate itch wit the view of developing more effective therapies for puritis. We previously discovered that the transcription factor Bhlhb5 is required for the survival of a subset of inhibitory interneurons in he spinal cord (which are here termed B5-I neurons) that are required for normal itch sensation; mice lacking these spinal interneurons suffer from persistent pathological itch. Since B5-I neurons are the first component of an itch circuit to be labeled genetically, studying these neurons provides us with a unique opportunity to unravel the neural basis of itch. Importantly, we have recently discovered that B5-I neurons are a specific subset of spinal interneurons that express dynorphin. This finding is important because dynorphin is a kappa opioid receptor (KOR) agonist, and KOR agonists have recently been shown to relieve itch in rodents and man. We therefore hypothesize that B5-I neurons function to inhibit itch, and that they do so in part through the release of dynorphin in the spinal cord. Here we propose to test this hypothesis in through 3 specific aims: Aim 1: Determine the degree to which B5-I neurons are specific to the regulation of itch. Aim 2: Dissect neural circuits in the dorsal horn using B5-I neurons as a molecular handle. Aim 3: Define the role of spinal dynorphin in itch. Results from these experiments are likely to have major clinical implications for people that suffer from chronic itch
because our findings will define a key cellular target for the development of future anti-itch therapies and they will provide important insight into the mechanism of KOR-mediated inhibition of itch.
描述(由申请人提供):慢性瘙痒(紫癜)是一种严重的疾病,导致生活质量严重下降。此外,这种情况比通常认识到的要普遍得多,这是去看皮肤科医生的最常见原因,尽管治疗通常无效。然而,虽然瘙痒是在皮肤中发起的,但i不仅仅是一种皮肤状况。相反,瘙痒是一种复杂且知之甚少的感觉,由外周、脊髓和大脑中的神经回路介导。因此,长期
我们的研究目的是为了更好地了解神经回路介导的瘙痒与开发更有效的治疗紫癜的观点。我们先前发现,转录因子Bhlhb 5是正常瘙痒感觉所需的脊髓中抑制性中间神经元(在此称为B5-I神经元)的亚组的存活所需的;缺乏这些脊髓中间神经元的小鼠患有持续性病理性瘙痒。由于B5-I神经元是瘙痒回路中第一个被标记为基因的组成部分,研究这些神经元为我们提供了一个独特的机会来解开瘙痒的神经基础。重要的是,我们最近发现B5-I神经元是表达强啡肽的脊髓中间神经元的特定子集。这一发现是重要的,因为强啡肽是一种κ阿片受体(KOR)激动剂,和KOR激动剂最近已被证明可以缓解瘙痒在啮齿动物和man. We因此假设,B5-I神经元的功能,以抑制瘙痒,他们这样做的一部分,通过释放强啡肽在脊髓。在这里,我们提出通过3个具体目标来测试这一假设:目标1:确定B5-I神经元对瘙痒调节的特异性程度。 目的二:以B5-I神经元为分子把手,解剖背角神经回路。 目的3:明确脊髓强啡肽在瘙痒中的作用。这些实验的结果可能对慢性瘙痒患者有重要的临床意义
因为我们的发现将为未来抗瘙痒疗法的发展确定一个关键的细胞靶点,并且它们将为KOR介导的瘙痒抑制机制提供重要的见解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sarah Elizabeth Ross其他文献
Sarah Elizabeth Ross的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sarah Elizabeth Ross', 18)}}的其他基金
Neural circuit basis for neurovascular coupling
神经血管耦合的神经回路基础
- 批准号:
10352382 - 财政年份:2021
- 资助金额:
$ 32.41万 - 项目类别:
Neural circuit basis for neurovascular coupling
神经血管耦合的神经回路基础
- 批准号:
10549806 - 财政年份:2021
- 资助金额:
$ 32.41万 - 项目类别:
Neural circuit basis for neurovascular coupling
神经血管耦合的神经回路基础
- 批准号:
10096478 - 财政年份:2021
- 资助金额:
$ 32.41万 - 项目类别:
Using dual intersectional genetics to understand and modulate itch
使用双重交叉遗传学来理解和调节瘙痒
- 批准号:
8490842 - 财政年份:2013
- 资助金额:
$ 32.41万 - 项目类别:
Using dual intersectional genetics to understand and modulate itch
使用双重交叉遗传学来理解和调节瘙痒
- 批准号:
8634026 - 财政年份:2013
- 资助金额:
$ 32.41万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 32.41万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 32.41万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 32.41万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 32.41万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 32.41万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 32.41万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 32.41万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 32.41万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 32.41万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 32.41万 - 项目类别: